Ribavirin Improves Early Responses to Peginterferon Through Improved Interferon Signaling

Jordan J. Feld, Glen A. Lutchman, Theo Heller, Koji Hara, Julie K. Pfeiffer, Richard D. Leff, Claudia Meek, Maria Rivera, Myung Ko, Christopher Koh, Yaron Rotman, Marc G. Ghany, Vanessa Haynes-Williams, Avidan U. Neumann, T. Jake Liang, Jay H. Hoofnagle

Research output: Contribution to journalArticle

88 Scopus citations

Abstract

Background & Aims: The therapeutic mechanisms of ribavirin for hepatitis C are unclear. Microarray analyses have shown that ribavirin increases induction of interferon-stimulated genes. We evaluated viral kinetics, serum cytokine expression, and viral mutagenesis during early stages of peginterferon therapy with and without ribavirin. Methods: Fifty patients with chronic hepatitis C virus (HCV) infection genotype 1 were randomly assigned to groups that were given peginterferon α-2a, with or without ribavirin, for 4 weeks; all patients then received an additional 44 weeks of combination therapy. First- and second-phase viral kinetics were evaluated. Serum levels of interferon-γ-inducible protein-10 (IP10), monokine induced by interferon-γ, and monocyte chemoattractant protein 1 were quantified as measures of the interferon-stimulated genes response. NS5A and NS5B were partially sequenced, and mutation rates were calculated. Results: The first-phase decrease in HCV RNA was similar between groups. Patients who received ribavirin had a more rapid second-phase decrease, compared with patients who did not receive ribavirin-particularly those with an adequate first-phase decrease (0.61 vs 0.35 log10 IU/mL/week; P = .018). At 12 hours, fold induction of serum IP10 was higher in patients given the combination therapy than those given peginterferon only (7.6- vs 3.8-fold; P = .01); however, the difference was greatest in patients with an adequate first-phase decrease in HCV RNA. IP10-induction correlated with first- and second-phase kinetics and with ribavirin serum concentrations on day 3. HCV mutation rates were similar between groups. Conclusions: Ribavirin improves the kinetics of the early response to therapy in patients with an adequate initial response to peginterferon. Induction of interferon-stimulated cytokines correlates with viral kinetics following ribavirin therapy, suggesting that ribavirin promotes interferon signaling.

Original languageEnglish (US)
Pages (from-to)154-162.e4
JournalGastroenterology
Volume139
Issue number1
DOIs
StatePublished - Jul 2010

Keywords

  • Hepatitis C
  • IP10
  • Interferon-stimulated Genes
  • Mechanism of Action
  • Viral Kinetics

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Ribavirin Improves Early Responses to Peginterferon Through Improved Interferon Signaling'. Together they form a unique fingerprint.

  • Cite this

    Feld, J. J., Lutchman, G. A., Heller, T., Hara, K., Pfeiffer, J. K., Leff, R. D., Meek, C., Rivera, M., Ko, M., Koh, C., Rotman, Y., Ghany, M. G., Haynes-Williams, V., Neumann, A. U., Liang, T. J., & Hoofnagle, J. H. (2010). Ribavirin Improves Early Responses to Peginterferon Through Improved Interferon Signaling. Gastroenterology, 139(1), 154-162.e4. https://doi.org/10.1053/j.gastro.2010.03.037